A multiple ascending dose study of a second generation formulation of ganaxolone is expected to begin in the second quarter of 2023.

Retifanlimab is a programmed death receptor-1-blocking antibody.

Rezzayo is expected to be available in the summer of 2023.

Fasedienol (PH94B) is a first-in-class, rapid-onset investigational pherine nasal spray.

CDC says infections with Pseudomonas aeruginosa have led to two additional deaths.

Increased relative risks noted for current or recent use of oral, injected, implanted, IUD progestogen-only contraceptives.

Statin use lower in Black and Hispanic vs White adults, including in the highest risk stratum.

Evinacumab is a fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3).

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.

Both products were discontinued because of a business decision and not due to safety or efficacy-related concerns.